Lung cancer hope: drug combo before surgery shows promise
NCT ID NCT05882513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the immunotherapy drug serplulimab together with chemotherapy before surgery can help shrink non-small cell lung cancer and improve outcomes. About 36 adults with stage IIA to IIIB lung cancer will receive the combination, then have surgery to remove the tumor. The goal is to see if this approach leads to no cancer cells left in the removed tissue and reduces the chance of the cancer coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?